The ELL2 (Eleven-Nineteen Lysine-Rich Leukemia protein 2) antibody is a tool used to study ELL2. a transcription elongation factor in the RNA polymerase II complex. ELL2 belongs to the ELL family, which regulates transcriptional elongation by preventing RNA polymerase II pausing. It plays critical roles in B-cell development, plasma cell differentiation, and immunoglobulin secretion. ELL2 interacts with the Super Elongation Complex (SEC) and other regulators like MYC to modulate gene expression. Dysregulation of ELL2 is linked to cancers, including multiple myeloma and leukemia, where its aberrant expression or mutations disrupt transcriptional control. Researchers use ELL2 antibodies in techniques like Western blotting, immunoprecipitation, and immunofluorescence to investigate its expression patterns, interactions, and functional mechanisms. The antibody aids in exploring ELL2's role in immune responses, oncogenesis, and potential therapeutic targeting. Studies also highlight its involvement in stress-induced transcription and coupling mRNA processing with elongation. As a biomarker, ELL2 expression levels correlate with disease progression in certain malignancies, making its antibody valuable for both basic research and clinical applications.